Curis Lifesciences Reports FY26 Revenue Growth of 21.16%; Strategic Investments Bolster Long-Term Expansion Plan
Ahmedabad, India | June 23, 2026Curis Lifesciences Limited, a pharmaceutical and healthcare products company, reported substantial revenue growth during the financial year (FY) 2026. The Company achieved total revenue of 6,062.88 Lakhs, marking a 21.16% increase year-over-year. For FY26, Curis also recorded an EBITDA of 1,141.09 Lakhs and a Profit After Tax (PAT) of 691.64 Lakhs.Despite achieving strong top-line growth, management noted that profitability margins were affected during the year due to strategic growth investments, temporary raw material cost pressures, and certain one-time expenses. However, the company...